Rubedo Life Sciences
PrivateLast Round
Series A
Apr 22, 2024
Total Funding Raised
$53.45M
Momentum Score
50 /100
Company Overview
Rubedo Life Sciences is a clinical-stage biopharmaceutical company focused on developing therapies for chronic age-related diseases by targeting senescent cells. The company's proprietary ALEMBIC™ drug discovery platform utilizes artificial intelligence and single-cell multiomics to engineer small molecules that selectively eliminate these pathological cells, which are key drivers of conditions like pulmonary, dermatological, and neurodegenerative disorders. By removing these harmful cells, Rubedo aims to restore tissue homeostasis and reverse the aging process at a cellular level. Founded in 2018, the company is venture-backed, having raised a $40 million Series A in 2024 led by Khosla Ventures and Ahren Innovation Capital to advance its lead candidates into clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rubedo Life Sciences Comps
Public and private peers based on sector, stage, and business model.
Rubedo Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 22, 2024 | ||||
| Grant | Feb 6, 2023 | ||||
| Seed | Dec 3, 2020 |
Key People
Founding team and executive leadership
Rubedo Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Refactor Capital | Seed, Series A |
| Khosla Ventures | Seed, Series A |
| Hevolution Foundation | Series A |
| LongeVC | Series A |
| Longevity Fund | Seed |
| 1521 Ventures | Series A |
| California Institute for Regenerative Medicine (CIRM) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 22, 2025
First patient dosed in Phase 1 trial for RLS-1496.
- Jan 1, 2025
Presented at the 12th Annual Dermatology Summit.
Rubedo Life Sciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Rubedo Life Sciences's valuation, stock price, and market status.
